ArticleJournal of virology1997
The potent enhancer activity of the polycythemic strain of spleen focus-forming virus in hematopoietic cells is governed by a binding site for Sp1 in the upstream control region and by a unique enhancer core motif, creating an exclusive target for PEBP/CBF.
Article in Journal of virology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- Human Lentiviral Gene Therapy Restores the Cellular Phenotype of Autosomal Recessive Complete IFN-γR1 Deficiency.Molecular therapy. Methods & clinical development · 2020Article
- In-vivo RGB marking and multicolour single-cell tracking in the adult brain.Scientific reports · 2014Article
- Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration.Brain : a journal of neurology · 2014Article
- Article
- Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.Leukemia · 2010Article
- A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells.Nature protocols · 2010Article
- Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Article
- The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.The Journal of clinical investigation · 2009Article
- Self-inactivating retroviral vectors with improved RNA processing.Gene therapy · 2004Article
- AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency.The Journal of experimental medicine · 2002Article
- Enhanced transgene expression in primitive hematopoietic progenitor cells and embryonic stem cells efficiently transduced by optimized retroviral hybrid vectors.Gene therapy · 2002Article
- High expression of transgenes mediated by hybrid retroviral vectors in hepatocytes: comparison of promoters from murine retroviruses in vitro and in vivo.Gene therapy · 2002Article
- In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity.Journal of virology · 2002Article
- Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells.Gene therapy · 2001Article
- Efficient intracellular retrotransposition of an exogenous primate retrovirus genome.The EMBO journal · 2000Article
- Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.Journal of virology · 2000Article
- Variegation of retroviral vector gene expression in myeloid cells.Gene therapy · 2000Article
- Design of 5' untranslated sequences in retroviral vectors developed for medical use.Journal of virology · 1999Article
- Characterization of a cis-acting sequence in the Pol region required to transfer human foamy virus vectors.Journal of virology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The polycythemic strain of the spleen focus-forming virus (SFFVp) contains the most potent murine retroviral enhancer configuration known so far for gene expression in myeloerythroid hematopoietic cells. In the present study, we mapped two crucial elements responsible for the high activity of the SFFVp enhancer to an altered upstream control region (UCR) containing a GC-rich motif (5'-GGGCGGG-3') and to a unique enhancer core (5'-TGCGGTC-3'). Acquisition of these motifs accounts for half of the activity of the complete retroviral enhancer in hematopoietic cells, irrespective of the developmental stage or lineage. Furthermore, the UCR motif contains the major determinant for the enhancer activity of SFFVp in embryonic stem (ES) cells. Using electrophoretic mobility shift assays, we show that the UCR of SFFVp, but not of Friend murine leukemia virus, is targeted by the ubiquitous transcriptional activator, Sp1. The core motif of SFFVp creates a specific and high-affinity target for polyomavirus enhancer binding protein/core binding factor (PEBP/CBF) and excludes access of CAAT/enhancer binding protein. Cotransfection experiments with ES cells imply that PEBP/CBF cooperates with the neighboring element, LVb (the only conserved Ets consensus in the SFFVp enhancer), and that the Sp1 motif in the UCR stimulates transactivation through the Ets-PEBP interaction. Putative secondary structures of the retroviral enhancers are proposed based on these data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.